Best of ASCO - 2014 Annual Meeting

 

Welcome

Cancer Angiogenesis and Metastases

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
18F-RGD PET/CT maybe useful to predict antiangiogenic response and adverse events.

Li Li

e24024

A multicenter retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.

Azka Ali

e24004

A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.

Nicolas Isambert

e24013

Adipokines derived from peritumoral visceral fat may promote lymphovascular invasion in colorectal cancer.

Yuji Miyamoto

e24023

Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.

Yu Liu

e24000

Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.

Marta Bonotto

e24014

AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.

Niki Karachaliou

e24003

Cancer of unknown primary: Experience at University Hospital Waterford.

Abdul Rehman Farooq

e24011

Characterization of a bone biorepository: Comparison of bone metastases from breast, prostate, renal, lung cancers, and myeloma.

Kerith Ruoyao Wang

e24019

Do high VEGFA and EGF levels in blood indicate liver metastases only?

Irina V. Kaplieva

e24007

Effect of cabazitaxel regimens on the growth of prostate cancer cells and the antitumor properties of PEDF.

Stephanie Filleur

e24002

Effect of chrysophanol on apoptosis induced by H2O2 in SH-SY5Y cells.

Si Fuchun

e24017

Evaluation of the efficacy of anti-angiogenic agents, alone and in combination with pemetrexed in the zebrafish model.

Yinghua Jin

e24005

Evolution of genomic instability in metastatic cancer.

Eric Yang Zhao

12008

Exosomes secreted from mesenchymal NSCLC cells to promote invasiveness and metastatic capability of recipient cells through UCHL1.

Yoshihisa Shimada

e24008

First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.

Christophe Le Tourneau

12024

IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).

Masaoki Ito

e24001

Pattern of bone metastasis of primary-known cancers spreading through vertebral venous plexus.

Ming-Yu Zhu

e24020

PPARγ agonist to inhibit tumor progression by modulating tumor microenvironment.

Guodong Huang

e24012

Sentinel lymph node as a clue to the primary site of cancer of unknown primary.

Yilin Shao

e24015

The impact of sample storage time on calculating tumor mutation burden (TMB).

Shifu Chen

e24022

The role and regulatory mechanism of NFIB in the metastasis of colorectal cancer.

Zhi-hang Zhou

e24009